This post is by Sponsored Content from Visual Capitalist
The following content is sponsored by RYAH MedTech
When Big Data and Plant-Based Medical Treatments Collide
Plant-based medical treatments are gaining popularity, as consumers become increasingly more privy to their various health benefits.
By 2030, the global botanical and plant-derived drug market is expected to reach $37.8 billion, at a compound annual growth rate (CAGR) of 3.5%.
Yet, while its future looks promising, the industry still some roadblocks to overcome. This graphic by RYAH MedTech looks at the key issues the plant-based medical industry is facing, and how big data can help solve them.
Key Industry Roadblocks
Plant-based treatments—such as medical cannabis—have come a long way in recent years. However, inconsistencies in regulation and dosage are making it hard for the industry to reach its full potential.
- Inconsistent regulation
Access to medical cannabis is still not equal across America, but legalization is becoming increasingly more widespread. For instance, Kansas passed a bill earlier this year that will legalize medical cannabis, as soon as the legislation is passed through the Senate.
- Inconsistent dosage standards
While consumers have expressed a desire for standardized dosing, there is no current jurisdiction to guide consumption. For example, studies have shown a lack of genetic consistency among different products that claim to use the same strain.
- Knowledge gap
Many physicians see the value in plant-based treatments, but some still don’t feel comfortable talking to patients about it. A recent survey found that 50% of Michigan-based healthcare respondents—where medical cannabis has been legal since 2008—didn’t (Read more...)